rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Progress in Medicinal Chemistry
  name:
    name part: Witty, David R.
    role:
      role term: creator
  name:
    name part: Cox, Brian.
  name:
    name part: ScienceDirect (Online service)
  type of resource: text
  genre: Electronic books.
  origin info:
    place:
      place term: cau
    place:
      place term: San Diego
    publisher: Elsevier
    date issued: 2020
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: remote
    extent: 1 online resource (262 p.).
  abstract: Progress in Medicinal Chemistry, Volume 59 provides a review of eclectic developments in medicinal G139 chemistry. Each chapter is written by an international board of authors, with this release focusing on Small Molecules - Giant Leaps for Immuno-Oncology, Reviewing P2X7, Reviewing ASK1, and Reviewing DNA-encoded libraries. Provides extended, timely reviews of topics in medicinal chemistry Contains targets and technologies relevant to the discovery of tomorrow's drugs Presents analyses of successful drug discovery programs.
  table of contents: Chapter Two: P2X7 receptor antagonists for the treatment of systemic inflammatory disorders -- 1. Introduction: P2X7 and inflammatory disorders -- 2. P2X7R antagonists in clinical trials -- 2.1. P2X7R antagonists in clinical trials for mood disorders -- 2.2. P2X7R antagonists in clinical trials for non-alcoholic steatohepatitis (NASH) -- 3. P2X7 receptor antagonists -- 3.1. Acyclic carboxamides -- 3.2. Heteroaromatic carboxamide cores -- 4. P2X7 PET ligands -- 5. Conclusion -- Acknowledgements -- References -- Further reading -- Chapter Three: Discovery and development of ASK1 inhibitors
  table of contents: 1. Introduction -- 2. Structure and regulation -- 2.1. Events downstream of ASK1 -- 2.2. Key factors interacting with ASK1 and composing the ASK1 signalosome -- 2.3. Key events regulating ASK1 activity -- 3. Cellular functions -- 3.1. Cell death -- 3.2. Inflammation -- 4. Involvement in disease -- 4.1. Neurodegenerative disorders -- 4.1.1. Alzheimerś disease -- 4.1.2. Parkinsonś disease -- 4.1.3. Huntingtonś disease -- 4.1.4. Amyotrophic lateral sclerosis -- 4.2. Cardiovascular diseases -- 4.3. Diabetes -- 4.4. Autoimmune and inflammatory diseases -- 4.4.1. Multiple sclerosis
  table of contents: 4.4.2. Rheumatoid arthritis -- 4.5. Osteoarthritis -- 4.5.1. Chronic pain -- 4.6. The role of ASK1 in liver diseases -- 4.7. The role of ASK1 in kidney diseases -- 4.8. The role of ASK1 in cancer -- 4.8.1. Functional studies demonstrating the role of ASK1 as a tumour suppressor -- 4.8.2. Functional studies demonstrating the role of ASK1 as oncogene -- 5. Discovery of small molecule ASK1 inhibitors -- 5.1. Introduction -- 5.2. Gilead sciences -- 5.3. Convergence/Galapagos -- 5.4. Eli Lilly -- 5.5. Enanta -- 5.6. Fronthera -- 5.7. Hepagene therapeutics
  note: Description based upon print version of record.
  note: 5.8. Institute of molecular biology and genetics, Kiev
  subject:
    topic: Pharmaceutical chemistry
  subject:
    topic: Chemistry, Pharmaceutical
  subject:
    topic: Chimie pharmaceutique
  subject:
    topic: Pharmaceutical chemistry
  classification: RS403
  classification: 615.19
  related item:
    title info:
      title: Progress in Medicinal Chemistry
    name:
      name part: Witty, David R.
    origin info:
      publisher: San Diego : Elsevier,c2020
  related item:
    title info:
      title: Issn Ser
  identifier: 0128211741
  identifier: 9780128211748
  identifier: 0128211733
  identifier: 9780128211731
  identifier: http://proxy.library.tamu.edu/login
  record info:
    record content source: EBLCP
    record creation date: 200509
    record change date: 20260327164427.6
    record identifier: in00005766359
    language of cataloging:
      language term: eng